ライフサイエンスコーパス: genomic medicine

1 have given great optimism for the impact of 'genomic medicine'.

2 sed here-is often viewed as within reach for genomic medicine.

3 nological disease is a critical challenge in genomic medicine.

4 arasite-resistant variants, advancing global genomic medicine.

5 ng a causal gene is a fundamental problem in genomic medicine.

6 anced structured knowledge representation of genomic medicine.

7 insights related to practicing and improving genomic medicine.

8 eciprocating and iterative processes towards genomic medicine.

9 kin disease are being created by advances in genomic medicine.

10 the human genome and ushering in the era of genomic medicine.

11 mes, and increase healthcare efficiencies in genomic medicine.

12 ity within the context of human genomics and genomic medicine.

13 the potential benefits of using EHR data in genomic medicine.

14 ticularly in populations underrepresented in genomic medicine.

15 s one of the biggest challenges to precision genomic medicine.

16 editing has the potential to further advance genomic medicine.

17 NA/RNA interactions and disease mutations in genomic medicine.

18 me sequenced as we transition into an era of genomic medicine.

19 late population-based research resources for genomic medicine.

20 ctive, we take stock of the nascent field of genomic medicine.

21 s that risk the successful implementation of genomic medicine.

22 the latest frontier surpassed in the era of genomic medicine.

23 nical outcomes is a fundamental challenge in genomic medicine.

24 sive prenatal DNA testing is the vanguard of genomic medicine.

25 dence-based development of best practices in genomic medicine.

26 inical use to minimize health disparities in genomic medicine.

27 ome critical to provide decision support for genomic medicine.

28 s made that these variants are the future of genomic medicine.

29 g, a prerequisite for physicians to practice genomic medicine.

30 inated the power of evolutionary thinking in genomic medicine.

31 mains a key challenge in systems biology and genomic medicine.

32 arch and describe the path towards an era of genomic medicine.

33 in dermatomyositis is leading down a path of genomic medicine.

34 vancing the aims of precision psychiatry and genomic medicine.

35 ctive, and critical component of research in genomic medicine.

36 nd challenges and barriers to integration of genomic medicine.

37 dictive, preventive, and personalized era of genomic medicine.

38 at many feel is prerequisite to personalized genomic medicine.

39 l of which form the basis for cardiovascular genomic medicine.

40 eering to tackle challenges in molecular and genomic medicine.

41 , and industrial biotechnology as well as on genomic medicine.

42 A visionary architect of genomic medicine.

43 f the human genome and better health through genomic medicine.

44 In the era of genomic medicine, AML treatment is customized to the pat

45 to use targeted therapies in the context of genomic medicine, analysis of the tumor in real-time may

46 proaches enable mechanism-based inference in genomic medicine and can help identify patients for sele

47 paper, we review clinical outcome studies in genomic medicine and discuss the important features and

48 nment research is thus a model of predictive genomic medicine and genomic screening.

49 estimates could help mitigate inequality in genomic medicine and improve our understanding of health

50 nderstanding of the predictive capability of genomic medicine and increase the opportunity to mitigat

51 g, and Blood Institute convened a workshop, "Genomic Medicine and Lung Diseases," to discuss the pote

52 strategies, and measures and in integrating genomic medicine and prevention into clinical practice.

53 h are all critical to the overall mission of genomic medicine and prevention, but they have yet to be

54 The second Newborn Sequencing in Genomic Medicine and Public Health (NSIGHT2) study was a

55 omains from the second Newborn Sequencing in Genomic Medicine and Public Health (NSIGHT2) study, a ra

56 The second Newborn Sequencing in Genomic Medicine and Public Health study was a randomize

57 In the past decade, significant progress in genomic medicine and technologic developments has revolu

58 Such studies herald the future of genomic medicine and the opportunity for personalized pr

59 etic studies and have major implications for genomic medicine and therapeutic development in South As

60 ncing (NGS) technologies have revolutionized genomic medicine and, as these technologies are being ap

61 ine, consumer information needs, delivery of genomic medicine, and challenges and barriers to integra

62 Psychiatry is intertwined with genomic medicine, and our understanding of what we call

63 of concepts such as translational medicine, genomic medicine, and personalized care, with measurable

64 slational research, slows the progression of genomic medicine, and worsens health disparities-a misse

65 urces in various research domains, including genomics, medicine, and pangenomics.

66 ases, and response to treatments, as well as genomic medicine application to the well-being of all hu

67 he impact of FINDbase, as a key resource for Genomic Medicine applications.

68 ard genomic equity to ensure the benefits of genomic medicine are accessible to all.

69 e requested from the Texas A&M Institute for Genomic Medicine, are readily available to the scientifi

70 hy; and 9990 controls from the Institute for Genomic Medicine at Columbia University Irving Medical C

71 The Genomic Medicine at Veterans Affairs (GenoVA) Study is a

72 For the ongoing Veterans Affairs Genomic Medicine at Veterans Affairs (GenoVA) Study we d

73 BD is nevertheless a challenging example for genomic medicine because the overall fraction of patient

74 or lessen the disease so that cardiovascular genomic medicine can become both predictive and preventi

75 Feline genomic medicine can decode human variants of uncertain

76 A fibre assay has a potential application in genomic medicine, cancer and stem cell research at the s

77 recruited through 13 National Health Service Genomic Medicine Centres or hospitals in England affilia

78 brought the vision of personal genomics and genomic medicine closer to reality.

79 copy number variants (CNVs) are important in genomic medicine, CNVs have not been systematically asse

80 Institute for Genomic Medicine (Columbia University Irving Medical Cen

81 ed study design and 4 key areas: outcomes of genomic medicine, consumer information needs, delivery o

82 Continued progress in genomic medicine could improve classification of HCCs ba

83 The promise of personalized genomic medicine depends on our ability to assess the fu

84 The success of personalized genomic medicine depends on our ability to assess the pa

85 on two types of knowledge most pertinent to genomic medicine: directed genic interactions such as pa

86 erging within the wider genomic research and genomic medicine ecosystems.

87 allenge for accurate diagnosis of LSS in the genomic medicine era is establishing gene-disease relati

88 the advancement of genetic technologies and genomic medicine for a variety of human diseases, includ

89 DESIGN, SETTING, AND PARTICIPANTS: The Genomic Medicine for Ill Neonates and Infants (GEMINI) s

90 To accomplish the goal of personalized genomic medicine for patients, close collaborations betw

91 dmixed ancestry, from the Slim Initiative in Genomic Medicine for the Americas study, and to approxim

92 e Mendelian disorders as part of the Brigham Genomic Medicine gene discovery initiative.

93 The era of genomic medicine has allowed acute myeloid leukemia (AML

94 e to our nascent era of personal genomes and genomic medicine has been made possible only because of

95 In recent years, genomic medicine has been moving from the bench to the b

96 Genomic medicine has entered clinical practice and the d

97 Now, genomic medicine has entered clinical practice as it per

98 This new field of genomic medicine has led to improvements in patient outc

99 Genomic medicine has now entered the clinical practice a

100 Genomic medicine holds promise to revolutionize care for

101 Genomic medicine holds the ultimate promise of revolutio

102 ) is a strong prerequisite for translational genomic medicine; however, low concordance between analy

103 a generated at the UC San Diego Institute of Genomic Medicine (IGC) using an Illumina NovaSeq 6000 th

104 nd harmonize measures for use across diverse genomic medicine implementation projects.

105 espite the increasing evidence of utility of genomic medicine in clinical practice, systematically in

106 DESIGN, SETTING, AND PARTICIPANTS: The Genomic Medicine in Ill Neonates and Infants (GEMINI) st

107 tic diagnosis affordable, enabling effective genomic medicine in monogenic diabetes.

108 se of a large quaternary referral center for genomic medicine in the Northwest of England.

109 ther low-resource settings, thereby bringing genomic medicine in these countries closer to clinical f

110 The expanding applications of nonviral genomic medicines in the lung remain restricted by deliv

111 rating approaches for performing research in genomic medicine, including the exploration of issues re

112 linical practice, systematically integrating genomic medicine information and knowledge into clinical

113 These national genomic-medicine initiatives are driving transformative

114 oaches and current progress made by national genomic-medicine initiatives in the UK, France, Australi

115 our diverse team collaborated to develop the Genomic Medicine Integrative Research (GMIR) Framework,

116 In the post-genomic era, genomic medicine interventions as a key component of per

117 We explore how genomic medicine is being used to obtain molecular diagn

118 led trials and 13 other studies assessed how genomic medicine is delivered and newer models of delive

119 A critical challenge in genomic medicine is identifying the genetic and environm

120 Genomic medicine is merging with clinical practice as ou

121 arities is immediately needed to ensure that genomic medicine is more equitable but will take a long-

122 However, measuring the utility of genomic medicine is not straightforward and has importan

123 However, the road to genomic medicine is paved with challenges and uncertaint

124 However, a major roadblock in genomic medicine is that for many variants, especially m

125 One of the primary goals of genomic medicine is to improve diagnosis through identif

126 as one of the initial steps in mainstreaming genomic medicine - is currently a focus in many countrie

127 target the epigenome as a whole, these true 'genomic medicines' lessen the need for precision approac

128 ew included prospective full-text studies of genomic medicine of both whole exome and genome sequenci

129 This systematic review found that genomic medicine offered various categories of utility f

130 Genomic medicine offers a growing number of methods to d

131 Genomic medicine, or the use of an individual's genomic

132 s (CNVs) presents a significant challenge in genomic medicine, primarily due to the complex nature of

133 Genomic medicine requires a robust evidence base of vari

134 e background information that can be used in genomic medicine research and application studies.

135 e and retain underrepresented populations in genomics medicine research.

136 r whole-genome sequencing (WGS) as part of a genomic medicine service.

137 ression patterns that can be used to improve genomic medicine strategies in several ways.

138 NPF cases were reviewed by a genomic medicine team, thus enabling bespoke informatic

139 In genomic medicine, the concept of genetically transitiona

140 ie Beutler Research Program of Excellence in Genomic Medicine, The Israel Science Foundation, the Wal

141 To overcome these disparities in genomic medicine, the Men of African Descent and Carcino

142 ng the database of the Manchester Centre for Genomic Medicine, this cohort study analyzed lymphocyte

143 s of human disease, are now being applied to genomic medicine through in silico integrative genomics.

144 When applying genomic medicine to a rare disease patient, the primary

145 of ContrastRank can be an important step in genomic medicine to enable genome-based diagnosis.

146 irections to further improve the delivery of genomic medicines to the brain.

147 The biggest challenge facing genomic medicine today is the development of new techniq

148 pact of ancestry-related biases in precision genomic medicine, we use 642 whole-genome sequences from

149 These challenges and opportunities for genomic medicine were central themes of the Golden Helix

150 of personalized medicine has been primarily genomic medicine, wherein it is hoped that the nucleotid

151 characteristics, most often single genes--to genomic medicine, which by its nature is comprehensive a

152 ly similar to the underpinning of predictive genomic medicine, which has the potential to shift medic

153 Genomic medicine, which uses DNA variation to individual

154 The next phase of genomic medicine will therefore require talented bioinfo